DRMA — Dermata Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $5.25m
- $2.09m
Annual cashflow statement for Dermata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.24 | -7.9 | -9.61 | -7.79 | -12.3 |
| Depreciation | |||||
| Non-Cash Items | -0.036 | 1.92 | 0.93 | 0.522 | 0.658 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.756 | 0.29 | -0.154 | 0.864 | 0.467 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.03 | -5.69 | -8.83 | -6.41 | -11.2 |
| Financing Cash Flow Items | 0 | — | — | -0 | -0.001 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.57 | 16 | 4.28 | 7.61 | 6.89 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.46 | 10.3 | -4.56 | 1.2 | -4.28 |